Melanotan II vs PT-141 (Bremelanotide)

The approved melanocortin drug and the compound it was derived from.

The distinction that mattersPT-141 was developed from Melanotan II specifically to isolate the sexual-arousal effect without the pigmentation effect. PT-141 is FDA-approved for one indication; Melanotan II is approved nowhere.

These are not equivalent in evidence PT-141 (Bremelanotide) is rated 5/5 and Melanotan II is rated 1/5 — a gap of 4 levels on our scale. Similar marketing does not mean similar proof.

	Melanotan II Research Use Only	PT-141 (Bremelanotide) FDA Approved
Evidence rating	1/5 Minimal Evidence rating 1 out of 5: Minimal	5/5 Very strong Evidence rating 5 out of 5: Very strong
Regulatory status	Not approved anywhere. Regulators in the US, UK, Australia and across the EU have issued explicit consumer safety warnings against it.	FDA-approved (2019) for acquired, generalized hypoactive sexual desire disorder in premenopausal women
Category	Sexual Health & Melanocortin	Sexual Health & Melanocortin
Drug class	Non-selective melanocortin receptor agonist (MC1R/MC3R/MC4R/MC5R)	Melanocortin receptor agonist (MC3R/MC4R) — cyclic heptapeptide
Route	Subcutaneous (illicit)	Subcutaneous autoinjector, as needed
Half-life	~1–2 hours	~2.7 hours
Studied in	Early academic studies of tanning and sexual function in the 1990s. No completed development program; superseded by the selective and approved afamelanotide.	RECONNECT phase 3 trials in premenopausal women with HSDD; earlier studies in erectile dysfunction including an intranasal formulation that was discontinued over blood-pressure effects.
Who should avoid it	Everyone — regulators globally advise against use. Anyone with atypical naevi, melanoma history or fair skin faces particularly elevated risk	Uncontrolled hypertension Known cardiovascular disease Pregnancy Postmenopausal women and men (outside approved indication)
Legal status	Illegal to sell for human use in the US, UK, EU and Australia. Not approved anywhere.	Prescription drug for its labelled indication. "Research grade" PT-141 sold online is unapproved.

Benefits — Melanotan II

Produces tanning without UV
The MC1R effect is real and reliable — melanogenesis without sun exposure.
Appetite suppression
MC4R-mediated; reported consistently by users.
Sexual arousal effects
The observation that led to the development of PT-141, which is the approved and far better-characterised alternative.

Benefits — PT-141 (Bremelanotide)

Statistically significant desire improvement
Phase 3 trials showed improvement in validated desire and distress scores versus placebo, sufficient for FDA approval.
On-demand rather than daily dosing
Taken ahead of anticipated activity, unlike flibanserin which requires continuous daily use.
Central mechanism
Addresses desire directly, useful where vascular-acting drugs are irrelevant to the problem.
No alcohol interaction restriction
A practical advantage over flibanserin, which carries alcohol warnings.

Risks & cons — Melanotan II

Melanoma and changing moles
Multiple case reports describe new or rapidly changing melanocytic lesions and melanoma diagnoses in users. It stimulates the exact cells involved.
Rhabdomyolysis
Case reports of severe rhabdomyolysis with acute kidney injury following use.
Priapism
Prolonged painful erection requiring emergency intervention has been reported; untreated priapism causes permanent damage.
Severe nausea and vomiting
Very common and often severe, particularly with the first doses.
Uncontrolled and unpredictable dosing
Sold as unregulated powder requiring self-reconstitution, with no standardised dose.

Risks & cons — PT-141 (Bremelanotide)

Nausea
The dominant adverse effect — roughly 40% of patients in trials, and about 1 in 8 required an antiemetic.
Transient blood pressure increase
Systolic rises of several mmHg with a compensatory heart-rate decrease. Contraindicated in uncontrolled hypertension or known cardiovascular disease.
Hyperpigmentation with repeated dosing
Focal darkening of the face, gums and breasts occurred in trials, more often with frequent use; may be permanent. Dosing is capped at 8 doses per month partly for this reason.
Modest average effect size
Statistically significant but clinically modest; response rates leave many patients unimproved.
Flushing and injection-site reactions
Common but generally mild.

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.